medigraphic.com
ISSN 0016-3813 (Print)

2019, Number 2

<< Back Next >>

Gac Med Mex 2019; 155 (2)

La esteroidogénesis en el síndrome de ovarios poliquísticos

Ventura-Arizmendi E, Hernández-Valencia M

Language: Spanish
References: 32
Page: 184-190
PDF size: 220.24 Kb.


ABSTRACT

Polycystic ovary syndrome is the most common endocrine disease in reproductive age, characterized by menstrual alterations, clinical or biochemical hyperandrogenism, and ultrasound-identified ovarian cysts. The neuroendocrine and metabolic alterations that accompany this condition involve the desensitization of the hypothalamus-pituitary-ovary axis, steroidogenesis and hyperandrogenism; recently, the role of insulin resistance has been explored. Hyperandrogenism has been established to be the main cause of polycystic ovary syndrome, due to enzymatic alterations in the steroidogenic pathway that cause luteinizing hormone over-stimulation because of quick pulses generated by gonadotropin-releasing hormones. Various growth factors of and cytokines inhibit the conversion of androgens into estrogens; activin and prostaglandins are also involved, even high levels of insulin participate in the characteristic deregulation of this syndrome.


REFERENCES

  1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1-13.

  2. Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev. 2001;1:111-151.

  3. Besser GM, McNeilly AS, Anderson DC, Marshall JC, Harsoulis P, Hall R, et al. Hormonal responses to synthetic luteinizing hormone and follicle stimulating hormone-releasing hormone in man. Br Med J. 1972; 3:267-271.

  4. Ciccone NA, Kaiser UB. The biology of gonadotroph regulation. Curr Opin Endocrinol Diabetes Obes. 2009;16:321-327

  5. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Rev Obstet Gynecol. 2011;4:45-51

  6. Liu C, Peng J, Matzuk MM, Yao HH. Lineage specification of ovarian theca cells requires multicellular interactions via oocyte and granulosa cells. Nat Commun. 2015;6:6934-6955.

  7. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122:42-52.

  8. Baskind NE, Balen AH. Hypothalamic-pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37 80-97.

  9. Gianetti E, Seminara S. Kisspeptin and KISS1R: a critical pathway in the reproductive system. Reproduction. 2008;136 295-301.

  10. Oride A, Kanasaki H, Mijiddorj T, Sukhbaatar U, Ishihara T, Kyo S. Regulation of kisspeptin and gonadotropin releasing hormone expression in rat placenta: study using primary cultures of rat placental cells. Reprod Biol Endocrinol 2015;13:90-98.

  11. Ezzat A, Pereira A, Clarke IJ. Kisspeptin is a component of the pulse generator for GnRH secretion in female sheep but not the pulse generator. Endocrinology. 2015;156:1828-1837.

  12. Hanchate NK, Parkash J, Bellefontaine N, Mazur D, Colledge WH, D’Anglemont- De-Tassigny X, et al. Kisspeptin-GPR54 signaling in mouse NO-synthesizing neurons participates in the hypothalamic control of ovulation. J Neurosci. 2012;32 932-945.

  13. Donoso AO, López FJ, Negro-Vilar A. Cross-talk between excitatory and inhibitory amino acids in the regulation of luteinizing hormone-releasing hormone secretion. Endocrinology. 1992;131:1559-1561.

  14. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev. 1996;17:121-155.

  15. Balen AH, Conway GS, Homburg R, Legro RS. Polycystic ovary syndrome. A guide to clinical management. EE. UU.: Taylor & Francis; 2005.

  16. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467-520.

  17. Barbieri RL. The endocrinology of the menstrual cycle. En: Rosenwaks Z, Wassarman PM, editores. Human Fertility. Methods and Protocols. EE. UU.: Humana Press; 2014.

  18. Otsuka F, McTavish K, Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev. 2011;78 9-21.

  19. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril. 1990;53:785-791.

  20. White D, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1995;42:475-481.

  21. Taylor AE, McCourt B, Martin K, Anderson EJ, Adams J, Schoebfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2248-2256.

  22. Barontini M, García-Rudaz M, Veldhius JD. Mechanisms of hypothalamic- pituitary-gonadal disruption in polycystic ovarian syndrome. Arch Med Res. 2001;32:544-552.

  23. Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, Caruso A, Mortensen MM, Rosenfield RL. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:1587-1594.

  24. Mason HD, Willis DS, Beard RW, Winston RM, Margara R, Frank S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and to concentrations of gonadotrophins and sex steroids in follicular fluid. J Clin Endocrinol Metab. 1994;79:1355-1360.

  25. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgensuppression test and a low-dose ACTH test. Hum Reprod. 2011;26: 3138-3146.

  26. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015,36:487-525.

  27. Kazer RR, Kessel B, Yen SS. Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1987;65:233-236.

  28. Qiao J, Feng HL. Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17-33.

  29. RefSeq: NCBI Reference Sequence Database [Sitio web]. EEUU: National Center for Biothechnology Information/National Library of Medicine; 2008.

  30. Peng HM, Im SC, Pearl NM, Turcu AF, Rege J, Waskell L, et al. Cytochrome b5 activates the 17,20-lyase activity of human cytochrome P450 17A1 by increasing the coupling of NADPH consumption to androgen production. Biochemistry. 2016;55:4356-4365.

  31. Balen, A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004;18 685-706.

  32. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanisms and implication for pathogenesis. Endocr Rev. 1997;18:774-800.




2020     |     www.medigraphic.com